TB-500: Complete Guide to the Thymosin Beta-4 Research Peptide

Thymosin beta-4's best-characterised job is actin handling. In 1991, researchers showed that an actin-sequestering peptide from human platelets was identical in sequence to Tβ4, and that Tβ4 binds actin monomers one-to-one and blocks their polymerisation. Because cells build their internal scaffolding, change shape and migrate by assembling actin filaments, a peptide that buffers free actin sits close to cell movement.^[2]

Later work mapped separate functions to short stretches of the molecule. A 2010 review describes an N-terminal tetrapeptide (Ac-SDKP) associated with reduced inflammation and fibrosis, a 15-residue N-terminal region linked to cell survival, and the central actin-binding domain around residues 17–23 (LKKTETQ) linked to angiogenesis, wound healing and cell migration.^[4]

That map matters for TB-500. In endothelial-cell migration assays and vessel-sprouting assays using chick aortic arches, the seven-amino-acid actin-binding motif matched full-length Tβ4 at around 50 nM, and peptides lacking the motif were inactive. The fragment does not contain the Ac-SDKP site, however, so activities tied to other regions of Tβ4 cannot be assumed for it. And when a 2024 study screened Ac-LKKTETQ and its breakdown products in fibroblast wound-healing assays, only the metabolite Ac-LKKTE showed significant activity; the authors noted that the biological effects of TB-500 itself had not been documented.^[3][4][7]

The foundational wound paper is a 1999 rat study. In a full-thickness skin-wound model, Tβ4 applied to the wound or given intraperitoneally increased re-epithelialisation by 42% over saline at day 4 and by up to 61% at day 7, and treated wounds showed more collagen deposition and new vessel growth.^[8]

Cardiac research raised the molecule's profile. In mice with a ligated coronary artery, Tβ4 activated the integrin-linked kinase and Akt survival pathway, improved early survival of heart-muscle cells and improved cardiac function. A 2007 study found Tβ4 essential for coronary vessel development in mice and able to mobilise progenitor cells from adult epicardial tissue.^[9][10]

The tendon evidence is much thinner. In a 2026 rat Achilles-repair study with 32 animals (eight per group), the TB-500 group showed a higher maximum load to failure and better histology scores than controls at four weeks. The authors called it exploratory, and it is one small animal study rather than a body of musculoskeletal evidence.^[11]

Reviews of the wider field say the same. A 2026 scoping review of six popular peptides, TB-500 included, found that 67% of the relevant publications used animal models and that human studies were few and mostly lacked robust controls. An orthopaedic primer published the same year concluded that Tβ4 and TB-500 promoted repair in preclinical models but that human orthopaedic data are lacking.^[12][13]

Not the TB-500 fragment, as far as the published record shows. The FDA states that it has not identified any human exposure data for drug products containing thymosin beta-4 fragment (LKKTETQ). Clinical development has instead used full-length Tβ4, aimed at skin, eye and heart applications, in formulations that include a topical gel, eye drops and an intravenous solution.^{[25][14][15][16][18]}

In a randomised, placebo-controlled Phase 1 study, four cohorts of ten healthy volunteers received intravenous synthetic Tβ4 or placebo, first once and then daily for 14 days; adverse events were infrequent and mild or moderate, with no dose-limiting toxicity. A Phase 2 trial of topical Tβ4 in 73 patients with venous leg ulcers, run at eight European sites, reported a safety profile comparable to placebo and efficacy findings that the authors framed as suggesting potential rather than proving benefit.^[15][16]

The eye is where Tβ4 went furthest. In dry eye, a nine-patient Phase 2 trial reported significant sign and symptom improvements versus vehicle, while a 72-subject Phase 2 trial missed both primary endpoints but improved several secondary measures. Two Phase 3 dry-eye trials, ARISE-2 (601 participants) and ARISE-3 (700 participants), are completed with results posted on ClinicalTrials.gov. None of this work studied TB-500, tendons, muscle or sports recovery.^{[17][18][19][20]}

Human safety data for TB-500 as it is sold do not exist. The FDA's summary for the fragment lists possible immunogenicity for certain routes of administration because of aggregation, peptide-related impurities, and missing information on whether it would cause harm. For full-length Tβ4, the Phase 1 and Phase 2 programmes above reported acceptable short-term tolerability for their specific formulations and populations.^[25][15][16]

The most discussed theoretical concern is cancer biology. The properties that interest wound researchers, cell migration and new blood vessel growth, are also steps in tumour spread. In a 2003 mouse study, melanoma cells engineered to overexpress Tβ4 formed larger tumours and about four times as many lung metastases as control cells, with more tumour blood vessels. That is an overexpression experiment inside cancer cells, not evidence that an external peptide causes cancer, but no long-term human data exist to settle the question either way.^[21]

Clinical reviewers flag the same gap. A 2026 review of unregulated injectable peptides lists product contamination, manufacturing impurities, pathological angiogenesis and carcinogenesis among the potential risks of unapproved compounds such as BPC-157 and TB-500, and the 2026 scoping review concluded that the claimed musculoskeletal benefits of these peptides remain unsubstantiated by current human trials.^[22][12]

WADA: the 2026 Prohibited List, in force from 1 January 2026, names 'thymosin-β4 and its derivatives e.g. TB-500' under S2.3, growth factors and growth factor modulators. Substances in this class are prohibited at all times, in and out of competition, and are non-specified substances. Doping laboratories have published methods to detect the acetylated fragment and its metabolites in urine and plasma.^[26][5][6]

FDA: 'thymosin beta-4, fragment (LKKTETQ), also known as TB-500' appears on the FDA page of bulk drug substances that may present significant safety risks in compounding, in the list of substances previously placed in category 2 whose nominations were later withdrawn. The FDA summary notes possible immunogenicity and states that no human exposure data have been identified.^[25]

EMA: no medicine containing thymosin beta-4 or TB-500 appears in the EMA's downloadable medicines data (checked September 2026), and there is no European public assessment report (EPAR). TB-500 has no centralised EU marketing authorisation.^[27]

TB-500 is often mentioned alongside BPC-157 and GHK-Cu, but the three are unrelated molecules. BPC-157 is a gastric-derived peptide whose repair literature is almost entirely preclinical: a 2025 systematic review found 35 preclinical studies and one clinical study. GHK-Cu is the copper complex of glycyl-histidyl-lysine, a tripeptide identified in blood serum in the 1970s.^[23][24]

Combining them is a separate question from understanding each one. The only controlled comparison we found is the 2026 rat Achilles study, in which BPC-157 plus TB-500 conferred no additional benefit over either peptide alone. The linked comparison pages cover the pairings in detail rather than repeating them here.^[11]

Peptyds supplies TB-500 as a lyophilised research compound for in-vitro laboratory work. Each release comes with a batch certificate covering identity and purity, linked on the product page, and the quality protocol explains what each document does and does not tell you.

What we do not do is turn the thymosin beta-4 literature into promises. Rat wound data, mouse heart data and eye-drop trials of full-length Tβ4 are research context. They are not evidence that TB-500 speeds recovery in people, and nothing on this page is guidance for personal use.^[8][18]